Evidence map›Paper›PMID 38672514›Full record

ReviewBiomolecules2024

Technical Advances in Circulating Cell-Free DNA Detection and Analysis for Personalized Medicine in Patients' Care.

Monica Sorbini, Tullia Carradori, Gabriele Maria Togliatto, Tiziana Vaisitti, Silvia Deaglio

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Observational
  13. Detection of Brain-Derived Cell-Free DNA in Plasma.Diagnostics (Basel, Switzerland) · 2024
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Monica SorbiniDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0009-0008-3308-7647
Tullia CarradoriDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Gabriele Maria TogliattoImmunogenetics and Transplant Biology Service, Città della Salute e della Scienza, 10126 Turin, Italy.
Tiziana VaisittiDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-3375-6985
Silvia DeaglioDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0003-0632-5036
University of Turin · IT

Funding

Ministero dell'Istruzione e del Merito D15D18000410001
6 · The paper itself

Abstract

Circulating cell-free DNA (cfDNA) refers to small fragments of DNA molecules released after programmed cell death and necrosis in several body fluids such as blood, saliva, urine, and cerebrospinal fluid. The discovery of cfDNA has revolutionized the field of non-invasive diagnostics in the oncologic field, in prenatal testing, and in organ transplantation. Despite the potential of cfDNA and the solid results published in the recent literature, several challenges remain, represented by a low abundance, a need for highly sensitive assays, and analytical issues. In this review, the main technical advances in cfDNA analysis are presented and discussed, with a comprehensive examination of the current available methodologies applied in each field. Considering the potential advantages of cfDNA, this biomarker is increasing its consensus among clinicians, as it allows us to monitor patients' conditions in an easy and non-invasive way, offering a more personalized care. Nevertheless, cfDNA analysis is still considered a diagnostic marker to be further validated, and very few centers are implementing its analysis in routine diagnostics. As technical improvements are enhancing the performances of cfDNA analysis, its application will transversally improve patients' quality of life.

Indexed as

Cell-Free Nucleic AcidsPrecision MedicineBiomarkersHumansNeoplasmsBiomarkersCell-Free Nucleic Acidscell-free DNAdigital PCRliquid biopsynext-generation sequencingnon-invasive diagnostics

Identifiers

PMID38672514
PMCPMC11048502
OpenAlexW4394953880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.